On August 6th, Gelonghui reported that Mengke Pharmaceuticals (688373.SH) intends to continue using temporarily idle raised funds not exceeding RMB 0.5 billion (including principal) for cash management, with a single maximum term not exceeding 12 months, and valid within 12 months from the date of approval by the company's board of directors. Within the above-mentioned amount and validity period, the funds can be rolled over and used.
盟科药业(688373.SH)：拟继续使用不超5亿元暂时闲置募集资金进行现金管理
Mengke Pharmaceutical (688373.SH): intends to continue using temporarily idle raised funds of no more than 0.5 billion yuan for cash management.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.